The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Utilization of intravenous bisphosphonates (IVBs) in patients with bone metastases (BMets) secondary to breast, lung, or prostate cancer (BC, LC, PC).
May Hagiwara
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Ze Cong
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Karen Chung
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Thomas E. Delea
Consultant or Advisory Role - Amgen
Research Funding - Amgen